{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:30:54Z","timestamp":1790667054648,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","respiratoryinvestigation.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.resinv.2015.05.003","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T11:59:04Z","timestamp":1439467144000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Update on the combination effect of macrolide antibiotics in community-acquired pneumonia"],"prefix":"10.1016","volume":"53","author":[{"given":"M.","family":"Emmet O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos I.","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2015.05.003_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/thx.2006.067371","article-title":"The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia","volume":"62","author":"Barlow","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2015.05.003_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MCC.0000000000000124","article-title":"Risks for multidrug-resistant pathogens in the ICU","volume":"20","author":"Martin-Loeches","year":"2014","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.resinv.2015.05.003_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03602.x","article-title":"Guidelines for the management of adult lower respiratory tract infections\u2014summary","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.resinv.2015.05.003_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1465-9921-15-75","article-title":"Predicting treatment failure in patients with community acquired pneumonia: a case-control study","volume":"15","author":"Martin-Loeches","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2015.05.003_bib5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00134-009-1734-7","article-title":"Are macrolides now obligatory in severe community-acquired pneumonia?","volume":"36","author":"Waterer","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib6","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections\u2014full version","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.resinv.2015.05.003_bib7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","article-title":"Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program","volume":"42","author":"Ferrer","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib8","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2015.05.003_bib9","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"Mandell","year":"2007","journal-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis"},{"key":"10.1016\/j.resinv.2015.05.003_bib10","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Martin-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/thoraxjnl-2012-202296","article-title":"British Thoracic Society. Single versus combination antibiotic therapy in adults hospitalised with community-acquired pneumonia","volume":"68","author":"Rodrigo","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2015.05.003_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1469-0691.2012.03783.x","article-title":"Impact of guideline-concordant antibiotics and macrolide\/\u03b2-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study","volume":"19","author":"Asadi","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.resinv.2015.05.003_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMp0804651","article-title":"Antibiotic-resistant bugs in the 21st century\u2014a clinical super-challenge","volume":"360","author":"Arias","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.22620","article-title":"Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases","volume":"49","author":"Brinker","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.resinv.2015.05.003_bib15","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib16","first-page":"318","article-title":"Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials","volume":"7","author":"Almalki","year":"2014","journal-title":"Am Health Drug Benefits"},{"issue":"21","key":"10.1016\/j.resinv.2015.05.003_bib17","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2014.4304","article-title":"Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia","volume":"311","author":"Mortensen","year":"2014","journal-title":"JAMA: J Am Med Assoc"},{"key":"10.1016\/j.resinv.2015.05.003_bib18","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/rccm.201002-0272CI","article-title":"Management of community-acquired pneumonia in adults","volume":"183","author":"Waterer","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib21","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA: J Am Med Assoc"},{"key":"10.1016\/j.resinv.2015.05.003_bib22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1378\/chest.13-1607","article-title":"Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia","volume":"145","author":"Laserna","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2015.05.003_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000320319","article-title":"Immunomodulatory effects of macrolide antibiotics \u2013 part 1: biological mechanisms","volume":"81","author":"Altenburg","year":"2011","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2015.05.003_bib24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1128\/AAC.45.6.1930-1933.2001","article-title":"Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa","volume":"45","author":"Tateda","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib25","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jac\/dkh223","article-title":"Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice","volume":"53","author":"Wu","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.intimp.2013.02.011","article-title":"Immunomodulatory effects of azithromycin on the establishment of lipopolysaccharide tolerance in mice","volume":"15","author":"Bosnar","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.resinv.2015.05.003_bib27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/41.5.505","article-title":"The effects of macrolides on the expression of bacterial virulence mechanisms","volume":"41","author":"Shryock","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-9255-11-5","article-title":"Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice","volume":"11","author":"Majhi","year":"2014","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.resinv.2015.05.003_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/sur.2013.076","article-title":"Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia","volume":"15","author":"McEvoy","year":"2014","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.resinv.2015.05.003_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1086\/529439","article-title":"Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia","volume":"46","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2015.05.003_bib31","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jac\/dkt475","article-title":"Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial","volume":"69","author":"Giamarellos-Bourboulis","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.resinv.2015.05.003_bib32","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jac\/dkm338","article-title":"Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro","volume":"60","author":"Anderson","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jiac.2013.10.010","article-title":"Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia","volume":"20","author":"Kohno","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1155\/2004\/461392","article-title":"Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults","volume":"11","author":"Weiss","year":"2004","journal-title":"Can Respir J"},{"issue":"1","key":"10.1016\/j.resinv.2015.05.003_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Euro Respir J"},{"key":"10.1016\/j.resinv.2015.05.003_bib36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jac\/49.3.433","article-title":"The in vivo\u2013in vitro paradox in pneumococcal respiratory tract infections","volume":"49","author":"Bishai","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1465-9921-14-52","article-title":"Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury","volume":"14","author":"Amado-Rodr\u00edguez","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2015.05.003_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.bjp.0706021","article-title":"Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression","volume":"144","author":"Sanz","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.resinv.2015.05.003_bib39","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1128\/AAC.42.6.1499","article-title":"Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro","volume":"42","author":"Kawasaki","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1164\/rccm.200711-1666OC","article-title":"Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease","volume":"178","author":"Hodge","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.intimp.2012.02.013","article-title":"Effect of azithromycin on natural killer cell function","volume":"13","author":"Lin","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.resinv.2015.05.003_bib42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/bbrc.1999.1917","article-title":"Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells","volume":"267","author":"Desaki","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.resinv.2015.05.003_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.112.200733","article-title":"A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-\u03baB inhibition","volume":"345","author":"Kobayashi","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.resinv.2015.05.003_bib44","doi-asserted-by":"crossref","first-page":"L75","DOI":"10.1152\/ajplung.00093.2005","article-title":"Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells","volume":"290","author":"Shinkai","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.resinv.2015.05.003_bib45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1179\/joc.2009.21.4.396","article-title":"Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway","volume":"21","author":"Ikegaya","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib46","first-page":"5S","article-title":"Clinical implications of the immunomodulatory effects of macrolides","volume":"117","author":"Tamaoki","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib47","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib48","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1128\/AAC.46.6.1746-1754.2002","article-title":"Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment","volume":"46","author":"Finch","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijantimicag.2004.07.013","article-title":"Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization","volume":"25","author":"Querol-Ribelles","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.resinv.2015.05.003_bib50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.idc.2012.11.004","article-title":"Does empirical therapy with a fluoroquinolone or the combination of a \u03b2-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?","volume":"27","author":"Ruhe","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.resinv.2015.05.003_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.03.00045202","article-title":"Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia","volume":"21","author":"Torres","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2015.05.003_bib52","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","article-title":"Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia","volume":"159","author":"Gleason","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib53","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1086\/591404","article-title":"Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project","volume":"47","author":"Bratzler","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2015.05.003_bib54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.resinv.2015.05.003_bib55","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1378\/chest.128.2.940","article-title":"The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia","volume":"128","author":"Weiss","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2015.05.003_bib56","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1503\/cmaj.080358","article-title":"Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials","volume":"179","author":"Vardakas","year":"2008","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.resinv.2015.05.003_bib57","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2015.05.003_bib58","first-page":"1068","article-title":"Authors\u05f3 response: single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia","volume":"68","author":"Rodrigo","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2015.05.003_bib59","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1164\/rccm.200311-1578OC","article-title":"Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia","volume":"170","author":"Baddour","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib60","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/01.CCM.0000266755.75844.05","article-title":"Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock","volume":"35","author":"Rodr\u00edguez","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib61","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib62","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/cc7774","article-title":"Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock\u2014does the dose matter?","volume":"13","author":"Pea","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.resinv.2015.05.003_bib63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Mart\u00ednez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2015.05.003_bib64","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib65","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/archinte.161.15.1837","article-title":"Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia","volume":"161","author":"Waterer","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.resinv.2015.05.003_bib66","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.123.5.1503","article-title":"Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database","volume":"123","author":"Brown","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2015.05.003_bib67","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Mart\u00ednez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2015.05.003_bib68","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/cc3934","article-title":"The impact of empiric antimicrobial therapy with a \u03b2-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia","volume":"10","author":"Mortensen","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.resinv.2015.05.003_bib69","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.06-1426","article-title":"Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones","volume":"131","author":"Metersky","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2015.05.003_bib70","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkp088","article-title":"Impact of intravenous {beta}-lactam\/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia","volume":"63","author":"Tessmer","year":"2009","journal-title":"J Antimicrob Chemother"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534515000763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534515000763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T01:05:15Z","timestamp":1599440715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534515000763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S2212534515000763"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2015.05.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726716422.793522923","asserted-by":"object"}]},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the combination effect of macrolide antibiotics in community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2015.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Japanese Respiratory Society. Published by Elsevier Japan KK All rights reserved.","name":"copyright","label":"Copyright"}]}}